AVCT:LSE-Avacta Group Plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 197.50

Change

+7.50 (+3.95)%

Market Cap

GBX 0.48B

Volume

1.12M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABC:LSE Abcam plc

-59.00 (-3.71%)

GBX3.60B 265.00 95.60
GNS:LSE Genus plc

-150.00 (-2.92%)

GBX3.35B 69.70 38.81
HCM:LSE Hutchison China MediTech Limit..

-16.00 (-3.72%)

GBX3.13B 17.41 N/A
PRTC:LSE PureTech Health plc

+1.00 (+0.24%)

GBX1.21B 2.68 1.59
OXB:LSE Oxford Biomedica plc

-24.00 (-2.34%)

GBX0.85B N/A 615.00
ERGO:LSE Ergomed plc

-90.00 (-6.95%)

GBX0.63B 103.60 49.78
SLN:LSE Silence Therapeutics plc

N/A

GBX0.52B N/A N/A
SNG:LSE Synairgen plc

-5.00 (-2.87%)

GBX0.35B N/A N/A
ARIX:LSE Arix Bioscience plc

-3.00 (-1.58%)

GBX0.26B 13.57 N/A
VRP:LSE Verona Pharma plc

N/A

GBX0.23B N/A N/A

ETFs Containing AVCT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 73.25% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.25% 100% A+ 98% A+
Trailing 12 Months  
Capital Gain 740.43% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 740.43% 98% A+ 100% A+
Trailing 5 Years  
Capital Gain 65.97% 59% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.97% 59% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 95.10% 88% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.10% 88% B+ 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 260.20% 10% F 10% F
Risk Adjusted Return 36.55% 55% F 56% F
Market Capitalization 0.48B 84% B 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.51 75% C 20% F
Price / Cash Flow Ratio -52.37 80% B- 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -66.23% 36% F 6% F
Return on Assets -28.43% 39% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.90 12% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector